Previous 10 | Next 10 |
Chinook Therapeutics (NASDAQ:KDNY) has priced its upsized underwritten public offering of 7,828,572 shares of its common stock at a price to the public of $14.00/share, for expected gross proceeds of $159.6M. In addition, it is offering pre-funded warrants to purchase 3,571,428 comm...
SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY) today announced the pricing of its upsized underwritten public offering of 7,828,572 shares of its common stock at a price to the public of $14.00 per share. In addition, and in lieu of common stock, Chinoo...
Chinook Therapeutics (NASDAQ:KDNY) announces that it intends to offer and sell 6M shares in an underwritten public offering. In addition, Chinook intends to grant the underwriters a 30-day option to purchase up to an additional 900,000 shares. Intends to use net proceeds to advance phase 3 AL...
SEATTLE, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that it intends to offer and sell 6,000,000 shares of its...
Chinook Therapeutics (NASDAQ:KDNY): Q3 GAAP EPS of -$0.69 beats by $0.15. Cash, cash equivalents and marketable securities totaled $204.8 million at September 30, 2021, compared to $250.4 million at December 31, 2020. Press Release For further details see: Chinook Therapeutics EPS beats...
SEATTLE, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the t...
Shares of Chinook Therapeutics (KDNY +28.6%) are surging today after the company released initial results from a phase 1/2 trial for BION-1301, a biologic for IgN neuropathy, a type of kidney disease. BION-1301 demonstrated >50% proteinuria reduction in patients with IgN neuropathy af...
Gainers: ReWalk Robotics (NASDAQ:RWLK) +37%, Ontrak (NASDAQ:OTRK) +35%, Alzamend Neuro (NASDAQ:ALZN) +32%, Chinook Therapeutics (NASDAQ:KDNY) +23%, Alimera Sciences (NASDAQ:ALIM) +22%. Losers: Deciphera Pharmaceuticals (NASDAQ:DCPH) -74%, Cali...
BION-1301 was well-tolerated and demonstrated rapid and sustained reductions in mechanistic biomarkers in patients with IgAN, including free APRIL, IgA and Gd-IgA1 levels BION-1301 demonstrated >50% proteinuria reduction in patients with IgAN after three to six mont...
Additional data to be presented from the ongoing phase 1/2 study of BION-1301 in patients with IgA nephropathy, including biomarker and proteinuria reductions Several presentations on the atrasentan clinical program, including translational research demonstrating E...
News, Short Squeeze, Breakout and More Instantly...
Chinook Therapeutics Inc Com Company Name:
KDNY Stock Symbol:
NASDAQ Market:
Chinook Therapeutics Inc Com Website:
Chinook Therapeutics, Inc. (NASDAQ: KDNY) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 2.86% on the day to $40.3. Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, dev...
SEATTLE, July 28, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the first patient with IgA nephropathy (IgAN) has been enr...
NEW YORK, NY / ACCESSWIRE / July 27, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Sculptor Capital Management Inc. (NYS...